INTRODUCTION
Coronary heart disease (CHD) is a major cause of morbidity and mortality. (1) This is particularly important in people with diabetes because they are at increased risk of having CHD, and to have multi-vessel disease when it occurs. (2) Patients with both diabetes and acute myocardial infarction (AMI) are more likely to present with acute pulmonary oedema, and this increased incidence of heart failure occurs despite similar infarct sizes and left ventricular ejection fractions. (3, 4) This observation suggests that the left ventricle in diabetes tolerates infarction poorly, irrespective of whether patients present with
ST elevation myocardial infarction (STEMI) or non-ST elevation myocardial infarction (NSTEMI).
Another important consideration in patients with AMI is the positive association between the admission glucose values and mortality in patients with and without diabetes. (5) There appears to be a graded relationship between admission glucose levels with major adverse cardiac events (MACE) both during hospital admission and post discharge. (6) Although several mechanisms have been proposed as to why there are worse outcomes in patients presenting with AMI and higher glucose concentrations on admission, it is still unclear whether high blood glucose is a marker for a sicker patient, as opposed to being causative for worse outcomes.
The optimal blood glucose cut-off value for the prediction of poor outcomes in AMI patients has not been determined. Recommendations for glycaemic control comes from 3 population groups, namely: critically ill patients from intensive care units, patients admitted with AMI, and general medical wards, (7, 8) all of which have their limitations. This may explain why the optimal strategy for the management of hyperglycaemia in patients with and without diabetes admitted with AMI is largely unknown. However, there is general consensus around the following points, hypoglycaemia should be avoided, and blood glucose be maintained between 7 -10mmol/l. (9) In South Africa, the prevalence of CHD is high, especially amongst the Asian Indian population, who present with multiple risk factors for AMI, which probably explains why they present at an early age. (10) More importantly, in addition to other conventional risk factors, self-reported diabetes was found in 46% of these patients with AMI. Considering the limited information available on glycaemic control on prognosis after an AMI, the present study therefore was undertaken to assess the utility of admission blood glucose for predicting MACE, both in hospital and 6 months' post-discharge in AMI patients with and without diabetes. Furthermore, we also sought to determine the optimal cut-off admission blood glucose level for predicting poor outcomes in these patients.
METHOD

Study population
In this retrospective, observational study, we enrolled patients admitted to the Coronary Care Unit (CCU) at R. 
Biochemical analyses
Blood samples were obtained intravenously from all subjects in the CCU immediately after hospital admission to quantify serum blood glucose concentrations and other biochemical measurements. Analyses were carried out using standard methods.
Plasma glucose levels were measured using the Dimension EXL (Siemens Healthineers). Furthermore, we sub-divided admission blood glucose levels into 3 groups, low (<7.8 mmol/l), medium (7.8 -10.9mmol/l) and high (≥11mmol/l), to assess whether an increasing degree of admission blood glucose levels was associated with an increased risk of MACE. This was performed to include the confounding influence of other variables (e.g. age, gender, etc.) in the multivariable adjusted estimates. Coefficients were exponentiated to present odds ratios (ORs) and 95% confidence intervals (CIs). Significance in the adjusted models was assessed at p <0.05. Model fit (adequacy) was assessed using goodness of fit tests. The
Youden index was used to identify the optimal breakpoints in blood glucose concentration in terms of its predictive capability for mortality and MACE. The discriminatory power was assessed using the AUC. An AUC ≥0.8 suggests good to excellent predictive capability. Sensitivity, specificity, positive predictive value, and negative predictive values based on the identified optimal cut-points were calculated. A p-value of <0.05 was taken as statistically significant.
RESULTS
The study cohort comprised 2 878 patients with AMI, of whom 2 269 (79%) presented with STEMI (Table I ). The mean age of the study population was 57.18 ± 11.47 years with a male preponderance (65%). Data were missing for certain variables such as abdominal girth (n=440, 15%) and HbA1c (n=574, 20%). Smoking (61%), self-reported diabetes (59%), hypertension (53%), previous myocardial infarction (12%) and previous angina (12%) were the most commonly observed risk factors. Fifty-eight percent of the patients had a family history of coronary artery disease, diabetes (43%), hypertension (38%) and cerebrovascular disease (19%). Of the 41% of patients who did not present with a self-reported history of diabetes, HbA1c
ADMISSION BLOOD GLUCOSE The median (interquartile range) admission blood glucose and HbA1c levels were 7.8 (5.8 -13.1)mmol/l and 6.9 (6.0% -9.0%), respectively. The majority of patients were on optimal medical therapy at hospital discharge. All patients in hospital with hyperglycaemia were treated with an insulin-based regime to try to maintain blood glucose levels less than 10mmol/l and hypoglycaemia was strictly avoided. Following discharge, 56%
ADMISSION BLOOD GLUCOSE Similarly, no significant association was found for the 38% (n=871) of STEMI patients who received thrombolysis.
A summary of the multivariable analysis for identifying factors associated with mortality by logistic regression analysis is shown in Figure 1 . In addition to cerebrovascular accidents (p<0.001), cardiogenic shock (p<0.01), complete heart block (p=0.008), ventricular arrhythmias (p=0,001), recurrence of infarction (p=0.003), cardiac failure (p=0.002), age ≥65 years (p<0.001), high creatinine (p<0.001) and Killip class ≥2 (p=0.027), patients with high admission blood glucose levels also conferred a significant increased odds of mortality (p=0.001).
We plotted the AUC with identified optimal cut-off value of admission blood glucose for predicting mortality in patients with AMI ( Figure 2 ). These analyses suggested that optimal blood glucose cut-off identified in this cohort (admission blood 
DISCUSSION
Individuals with diabetes mellitus are at increased risk for the development of AMI (12, 13) and diabetes is now considered a coronary risk equivalent by the National Cholesterol Education
Programme. (14) The current study confirms these findings with the prevalence of self-reported diabetes being present in 59%
of patients with AMI. An additional 377 patients were diagnosed with diabetes based on HbA1c levels, suggesting that the more accurate prevalence of diabetes in the study cohort was 72%. Given the widespread use of HbA1c in the diagnosis and management of patients with diabetes, we believe that the use of HbA1c in the majority of patients is a key strength of our study. The presence of elevated levels of HbA1c levels in these patients makes stress hyperglycaemia a less likely diagnosis, indicating that the metabolic abnormality preceded the infarction. These results concur with a recent local study which compared different diagnostic criteria for the detection of undiagnosed diabetes in 896 acute myocardial infarction patients (data unpublished). Of interest is that using HbA1c criteria, 32% of patients were diagnosed with diabetes while 47% were diagnosed with pre-diabetes, highlighting the increased prevalence of diabetes in this geographical region.
Our findings support the importance of screening for glucose abnormalities in patients hospitalised for AMI to strengthen secondary preventative efforts (including medical and lifestyle interventions) in a high-risk patient population.
Patients in the study also presented with multiple conventional risk factors such as smoking, hypertension, dyslipidemia, obesity, and a family history of vascular disorders, which may also possibly have contributed to the occurrence of AMI. Therefore, a comprehensive risk factor intervention strategy is required over and above strict glycaemic control to decrease the risk of complications following an AMI.
Several studies have reported a positive association between higher glucose concentrations, adverse clinical outcomes and mortality in patients with AMI both during hospital admission and post-discharge. (15, 16) Although the mechanisms by which hyperglycaemia cause harmful effects in patients with AMI are unclear, it has been suggested that a wide variety of pathophysiological changes are involved. These include volume depletion, increased free fatty acid production, decreased nitric oxide availability, increased coagulopathy and atherogenesis, endothelial dysfunction and increased circulating inflammatory cytokines. (17) (18) (19) Our 
The pathogenesis of heart failure in diabetes is multifactorial, but can be largely attributable to ischaemic heart disease, hypertension, diabetic cardiomyopathy and extracellular fluid volume expansion. (21, 22) More importantly, cardiac metabolism is altered in the presence of heart failure due to decreased mitochondrial function as a result of the accumulation of medium and long chain acyl-carnitine, increased ketone metabolism and the accumulation of lactate and branch chain amino acids. (23) Patients with diabetes, therefore, are at increased risk for the development of heart failure and the prevention of heart failure is becoming a major emerging research and treatment goal such as the discovery of the sodium-glucose co-transporter 2 (SGLT2) inhibitors for the treatment of diabetes and coexistent heart failure. (24) Thus, our findings provide a contemporary picture in a South African cohort of patients suggesting that elevated admission blood glucose levels are a prognostic marker for in-hospital and short-term adverse clinical outcomes in patients with AMI.
Furthermore, following multivariable logistic regression analyses of clinical and laboratory parameters associated with mortality, in addition to cerebrovascular accidents, cardiogenic shock, complete heart block, ventricular arrhythmias, recurrence of Volume 16 Number 2 infarction, cardiac failure age ≥65 years, high creatinine and Killip class ≥2, high admission blood glucose also conferred a significant increased odds of mortality.
In addition to the admission value, a graded relationship has been found between increasing blood glucose levels and MACE.
However, the optimal glucose cut-off value for the prediction of poor outcomes has not been determined. We also investigated the optimal cut-off admission blood glucose value as determined via a ROC curve for predicting in-hospital and 6
months' mortality in patients with AMI. The optimal cut-off point was an admission blood glucose value of 8.5mmol/l, which has only modest capability for predicting mortality.
Similarly, the optimal cut-off point for MACE was an admission blood glucose value of 8.1mmol/l, which also displayed modest predictive capability. Hence, these cut-off values are only exploratory and further studies are required before they may serve as indicators of clinical reference for secondary prevention for improving the prognosis after AMI. We are unaware of any large studies in South Africa that examined the prevalence and predictive value of admission blood glucose in patients presenting with AMI and our study may provide important epidemiological insight into elevated admission blood glucose as a risk factor for MACE. Although HbA1c, which reflects metabolic and glycaemic control, has been shown to be a significant predictor of MACE after AMI, (25) elevated admission blood glucose may serve as a cost-effective and easily obtainable alternate prognostic marker.
LIMITATIONS
Several potential limitations need acknowledgement. First, this was a retrospective observational study with few variables having missing data, which may have caused selection bias. This shortcoming was minimised by using standardised methods for data collection, while the large study population allowed for greater statistical power. Second, the follow-up period of the patients was only 6 months; thus, it is necessary to investigate the longer-term relationship between admission blood glucose and MACE. Third, although we reveal that elevated admission blood glucose was associated with unfavorable in-hospital and 6-month outcome, the effects of treating hyperglycaemia after admission were not assessed. Finally, 62% of patients with STEMI did not receive thrombolytic therapy because of late presentation or standard contraindications, while only 38% of patients underwent coronary angiographic studies, with no patients receiving primary PCI according to timeline-based guidelines. Therefore, these data should be interpreted with caution, particularly with respect to the various MACE outcomes observed. This is due to the fact that patients are referred to another hospital with long waiting lists for cardiac catheterisation, and a large number of them declined intervention or did not have coronary angiograms performed because of other co-morbidities.
CONCLUSIONS
The findings from the present study show that patients have multiple risk factors for AMI with diabetes playing a central role.
Elevated admission blood glucose in AMI patients is an important indicator for in-hospital and short-term MACE, with a graded increase in the risk of MACE demonstrated with increasing levels of admission blood glucose. Although the optimal blood glucose target in AMI patients with hyperglycaemia is uncertain, the cut-off admission blood glucose value for predicting MACE and mortality in our study has only modest predictability and further research is required to improve the performance of these measures for routine clinical use.
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